Explore how rural hospitals are adapting to Medicaid cuts and workforce challenges through innovation and targeted strategies to maintain healthcare access in rural America.
Novo Nordisk and Eli Lilly agree to lower GLP-1 drug prices in exchange for expanded Medicare and Medicaid coverage, marking a major shift in U.S. drug pricing and access.
The 2026 Medicare home health final rule release is delayed due to the government shutdown. Proposed 9% reimbursement cuts spark industry-wide concern and strategic responses from key providers and advocacy groups.
CMS issues National Coverage Determination for FDA-approved renal denervation treatment under Coverage with Evidence Development for uncontrolled hypertension in Medicare patients.
Stellar Health's MSSP ACO surpasses Medicare average savings with $5M saved in 2024, leveraging tech-enabled micro-incentives to improve provider performance and patient outcomes in value-based care.
Explore how political donations and regulatory delays have impacted Medicare coverage and spending on costly skin substitute products lacking scientific validation.
Special Needs Plans (SNPs) are driving significant growth in Medicare Advantage enrollment in 2025, with chronic condition and dual-eligible SNPs leading gains. Institutional SNPs decline amid evolving care models.
FirstMedicare Direct will close operations by end of 2025, affecting 6,000 Medicare Advantage members. This exit highlights challenges in the Medicare Advantage insurance market.
Medicare Advantage market pivots from growth-at-any-cost to profitability-first amid CMS regulatory tightening and rising medical costs. Key strategic shifts include operational efficiency, agility in member services, and investment in clinical programs to improve outcomes and reduce total care costs.
Explore essential insights into Medigap Plans F, G, and N, focusing on coverage, enrollment periods, and regulatory nuances critical for U.S. insurance professionals advising Medicare beneficiaries.
